Compare Neurocrine Biosciences Inc (NBIX) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs IAC/Interactivecorp — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while IAC/Interactivecorp trades at $37.76 (market cap $2.86B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.5× IAC/Interactivecorp's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals.
| NBIX | PPLI | |
|---|---|---|
Market Cap | $15.77B | $2.86B |
Sector | Health | Media |
52-Week High | $185.50 | $47.62 |
52-Week Low | $123.10 | $31.52 |
Enterprise Value | $15.78B | $3.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
PPLI trades at $38.38, down 1.56% in the last session, with a bearish technical signal but attractive valuation ratios including a P/E of 6.49 and P/B of 0.56. Recent Q2 2026 earnings beat expectations with EPS of $6.77, driven by gains from its MGM stake, though revenue declined to $2.39B in 2025. The company is focusing on monetizing non-core assets and capital allocation toward its media business and MGM holdings, as highlighted in recent conference presentations.
The outlook is mixed: strong analyst support with a $58.80 consensus price target and 69% buy ratings offers upside, but risks include volatile earnings, declining revenue trends, and a shareholder investigation. Investors should weigh the deep valuation discount against execution challenges in asset sales and digital growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
